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Although pathological examination serves as the gold standard for breast cancer diagnosis, it requires labor-
intensive sample preparation and time-consuming evaluation, resulting in long turn-around time and extensive 
infrastructure. We have developed a simple molecular imaging platform that can quickly assess patient’s 
samples and provide a molecular signal to reflect disease pathology as an alternative to traditional pathology, 
particularly for applications in low resource settings. We identified Heat shock protein 90 (Hsp90) as a molecular 
target to diagnose breast cancer as it is overexpressed on the surface of all breast cancer cell subtypes to 
orchestrate stress response to cancer formation. Based on this feature, we have established a non-invasive and 
rapid molecular imaging approach to quantify Hsp90 expression on breast tissue biopsies using a FITC tethered 
Hsp90 inhibitor (HS-27) that binds to surface Hsp90 of breast cancer cells. A wide-field, high resolution, 
handheld fluorescent microscope referred to as the Pocket Mammoscope has been developed to perform rapid 
non-contact Hsp90 fluorescent imaging of entire tissue biopsies at point of care. 
The Pocket Mammoscope uses a concentric excitation blue LED source (470±20 nm) a band-pass emission 
filter (534±26nm) for HS-27 fluorescence emission and a CMOS detector  for imaging(Figure 1A). It is capable 
of 3-52X magnification and can perform both wide-field and high-resolution imaging by changing the working 
distance using a user-controlled slider mechanism on the body of the scope. In wide-field imaging mode, the 
Pocket Mammoscope achieves a FOV of 35 mm and an optical resolution of 24.8 µm while high-resolution 
mode achieves a FOV of 8.5 mm and an optical resolution of 8.77 µm. This dual imaging mode of Pocket 
Mammoscope allow us to image entire region of a 
core needle biopsy in one snapshot using the wide-
field mode and zoom in to the regions of interest using 
a high-resolution mode (Figure 1B).  
In our pilot clinical studies, we also demonstrated the 
feasibility of using the Pocket Mammoscope for 
Hsp90 fluorescent imaging on patient breast core 
needle biopsies. We showed that HER2+ biopsy has 
significantly higher HS-27 signal compared to benign 
breas ttissues (Figure 1C). To examine the sensitivity 
and specificity of Hsp90 imaging, we used features 
from the image in a Gaussian support vector machine 
(GSVM) classifier. A Receiver Operating 
Characteristics (ROC) curve shows specificity (100%) 
and sensitivity (86%) of Hsp90 for distinguishing 
malignant tumor biopsies (n = 27) from benign 
biopsies (n = 10) (Figure 1D). We are further 
optimizing our Hsp90 staining protocol and 
prototyping an automated staining platform to 
ensure uniform and consistent staining and 
washing of clinical biopsy samples as a way to 
improve sensitivity.  By integrating an automated 
staining platform with Pocket Mammscope, our 
diagnostic platform could ultimately serve as an 
alternative to traditional pathology at a point-of-
care setting. 
Figure 1 – (A) Pocket Mammoscope: (1) first linear film 
polarizer (2) concentric illumination with LEDs (470±20 
nm) (3) aluminum holder (4) emission filter (535±26nm) 
(5) second linear film polarizer. (B) Representative 
image of cancerous breast biopsy captured by Pocket 
Mammoscope in wide-field (left) and high-resolution 
(right) modes. (C) Representative image of patient 
breast biopsies captured by Pocket Mammoscope: 
HER2+ (top) and Mammoplasty (bottom). (D) HS-27 
ROC for distinguishing malignant tumor from benign 
tissue based on the top 1% of pixels 
 
